Anthem Biosciences credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
51.151.1
−889−889
0.02×0.02×
−0.29×−0.29×
0.06×0.06×
−1.12×−1.07×
101.50×101.50×
1.7%1.7%
As filed — company-reported covenants
1.18×0.02×
28.54×143.55×
163.93×120.56×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ANTHEM₹805.70

Anthem Biosciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABGLAXOAJANTPHARMIPCALABABBOTINDIAMEDANTAGLENMARKMcap ₹45,257 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt51.151.1
Net Debt-889.4-889.4
Total Debt/Equity0.020.02
Net Debt/Equity-0.29-0.29
Total Debt/EBITDA0.060.06
Net Debt/EBITDA-1.07-1.12
Interest Coverage (EBIT/Interest)101.50101.50
Total Debt/Total Capital %1.651.65
As Filed — company-reported covenants
Debt/Equity (as filed)0.021.18
Debt Service Coverage (as filed)143.5528.54
Interest Service Coverage (as filed)120.56163.93
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.